Granules India has earmarked a capex of around Rs 1,000 crore which it aims to invest over the next three financial years on a new manufacturing facility and on expanding production capacities at existing plants. During FY22, it expects to spend Rs 400 crore and the rest of the Rs 600 crore is spread over FY23 and FY24.
The company plans to invest about Rs 180 crore on a Multiple Units Pellet System (MUPS) block, around Rs 250 crore on expanding active pharmaceutical ingredients (API) capacity, Rs 320 crore on a new formulation plant and another Rs 30 crore on expansion of a facility near Hyderabad which rolls out paracetamol and metformin.
Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).
